CSK
ENSG00000103653
Target class
Kinase
Chromosome
15
- Chemical probe available
- No
- Target name
- CSK
- Gene name
- C-terminal Src kinase
- Gene symbol
- CSK
- Protein name
- Tyrosine-protein kinase CSK (EC 2.7.10.2) (C-Src kinase) (Protein-tyrosine kinase CYL)
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Csk family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 225.74
- Tissue specificity (Gini)
- 0.409
- Tissue specificity (tau)
- 0.855
- KEGG gene identifiers
- hsa:1445
- Protein interaction confidence
- 0.824872
- Protein interaction partners
- 39
- R-HSA-180292
- R-HSA-202427
- R-HSA-354192
- R-HSA-389948
- R-HSA-5674135
- R-HSA-6802946
- R-HSA-6802948
- R-HSA-6802952
- R-HSA-6802955
- R-HSA-9013407
- R-HSA-9649948
- R-HSA-9656223
- R-HSA-9706369
- End position
- 74803198
- Start position
- 74782055
- Chromosome
- 15
- Strand
- Forward
- Cytoplasm . Cell membrane . Note=Mainly cytoplasmic, also present in lipid rafts. .
- Cytosol
- Vesicles
- Tissue specificity (tau)
- 0.855188
- Expression inequality (Gini)
- 0.40878
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 225.74
- Spleen
- 158.27
- Whole Blood
- 141.97
- Esophagus - Mucosa
- 102.95
- Small Intestine - Terminal Ileum
- 54.49
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes225.74
- Spleen158.27
- Whole Blood141.97
- Esophagus - Mucosa102.95
- Small Intestine - Terminal Ileum54.49
- Lung48.85
- Vagina48.2
- Skin - Sun Exposed (Lower leg)45.67
- Cells - Cultured fibroblasts44.48
- Cervix - Endocervix43.24
- Brain - Cerebellar Hemisphere40.4
- Brain - Cerebellum40.18
- Cervix - Ectocervix39.89
- Skin - Not Sun Exposed (Suprapubic)39.82
- Uterus38.72
- Prostate37.58
- Colon - Transverse35.64
- Testis33.86
- Minor Salivary Gland33.34
- Fallopian Tube32.7
- Thyroid32.22
- Nerve - Tibial30.06
- Pituitary29.64
- Ovary29.61
- Bladder29.21
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0031295
- GO:0042997
- GO:0050852
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0070062
- GO:0004713
- GO:0005515
- GO:0034236
- GO:0042802
Related records
Trials (471)
- A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
- A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
- A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
- A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
- A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.
- A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer
- A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.
- A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
- A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
- A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
- A Phase II Study of Apatinib in STS Patients
- A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
- A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
- A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
- A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
- A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
- A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
Drugs (2)
- Ponatinib
- Rivoceranib